- Home
- KRP vs MDXG Comparison
KRP vs MDXG Comparison
Compare KRP & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- MDXG
- Stock Information
- Founded
- KRP 2013
- MDXG 2006
- Country
- KRP United States
- MDXG United States
- Employees
- KRP N/A
- MDXG N/A
- Industry
- KRP Oil & Gas Production
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- MDXG Health Care
- Exchange
- KRP Nasdaq
- MDXG Nasdaq
- Market Cap
- KRP 1.3B
- MDXG 1.1B
- IPO Year
- KRP 2017
- MDXG N/A
- Fundamental
- Price
- KRP $16.00
- MDXG $9.06
- Analyst Decision
- KRP Strong Buy
- MDXG Strong Buy
- Analyst Count
- KRP 5
- MDXG 5
- Target Price
- KRP $19.60
- MDXG $12.00
- AVG Volume (30 Days)
- KRP 494.4K
- MDXG 1.1M
- Earning Date
- KRP 11-07-2024
- MDXG 10-30-2024
- Dividend Yield
- KRP 10.96%
- MDXG N/A
- EPS Growth
- KRP N/A
- MDXG N/A
- EPS
- KRP 0.52
- MDXG 0.52
- Revenue
- KRP $325,011,605.00
- MDXG $342,804,000.00
- Revenue This Year
- KRP $19.44
- MDXG $9.56
- Revenue Next Year
- KRP $5.26
- MDXG $9.19
- P/E Ratio
- KRP $30.69
- MDXG $17.47
- Revenue Growth
- KRP 30.47
- MDXG 10.93
- 52 Week Low
- KRP $14.26
- MDXG $5.47
- 52 Week High
- KRP $17.07
- MDXG $9.49
- Technical
- Relative Strength Index (RSI)
- KRP 45.21
- MDXG 78.62
- Support Level
- KRP $15.57
- MDXG $8.94
- Resistance Level
- KRP $16.53
- MDXG $9.49
- Average True Range (ATR)
- KRP 0.30
- MDXG 0.45
- MACD
- KRP -0.06
- MDXG 0.20
- Stochastic Oscillator
- KRP 30.28
- MDXG 85.86
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.